telmisartan + simvastatin

Telmisartan + simvastatin is a fixed-dose combination of two small-molecule drugs: telmisartan, an angiotensin II receptor blocker (ARB) with additional peroxisome proliferator-activated receptor gamma (PPARγ) agonist activity, and simvastatin, a 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin). This combination is intended to address both hypertension and hypercholesterolemia, two significant cardiovascular risk factors. Telmisartan works by blocking angiotensin II type 1 (AT1) receptors, thereby lowering blood pressure and exerting vasoprotective effects, while also activating PPARγ, which may confer additional endothelial and metabolic benefits. Simvastatin reduces cholesterol synthesis in the liver by inhibiting HMG-CoA reductase, leading to decreased LDL cholesterol and overall atherogenic risk. Combination therapy with these agents has been shown in preclinical studies to have an additive effect on increasing the number and function of endothelial progenitor cells (EPCs), suggesting synergistic cardiovascular protective mechanisms operating through PPARγ-dependent pathways (for telmisartan) and PI3K/Akt signaling (for simvastatin)[1][3][5].

Other names

telmisartan and simvastatin combinationtelmisartan / simvastatin combination